Company Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity.
The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
The company was incorporated in 2016 and is headquartered in Foster City, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Amy Burroughs |
Contact Details
Address: 1065 East Hillsdale Boulevard, Suite 100 Foster City, California 94404 United States | |
| Phone | 650 525 5535 |
| Website | ternspharma.com |
Stock Details
| Ticker Symbol | TERN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001831363 |
| CUSIP Number | 880881107 |
| ISIN Number | US8808811074 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Amy L. Burroughs M.B.A. | Chief Executive Officer and Director |
| Melita Sun Jung | Chief Business Officer |
| Andrew W. Gengos | Chief Financial Officer |
| Dr. Jeffrey R. Jasper Ph.D. | Senior Vice President of Research |
| Dr. Emil T. Kuriakose M.D. | Chief Medical Officer |
| Scott Harris | Chief Development Officer |
| Debra Sieminski | Senior Vice President of Medical Affairs |
| James Kanter | Senior Vice President of CMC |
| Yasameen Qazen | Senior Vice President of Regulatory Affairs and Quality Assurance |
| David Eric Strauss | Vice President of Finance and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| May 7, 2025 | SCHEDULE 13G | Filing |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 20, 2025 | 10-K | Annual Report |
| Mar 20, 2025 | 8-K | Current Report |